Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical HDAC inhibitor, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL). The development of SHP-141 is being supported through a Therapeutic Accelerator Program partnership with the Leukemia & Lymphoma Society, which is providing funding of up to $3.3 million. Shape is a Healthcare Ventures funded focused company founded by James E. Bradner, M.D., and Ralph Mazitschek, Ph.D. |
03.04.2013Shape Pharmaceuticals Provides Update on SHP-141 Topical HDAC Inhibitor Clinical Development for Cutaneous T Cell Lymphoma |